
Neurophysiologic Biomarkers in Neuropsychiatric Disorders
Etiologic and Treatment Considerations
Series: Advances in Neurobiology; 40;
- Publisher's listprice EUR 235.39
-
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 8% (cc. 7 988 Ft off)
- Discounted price 91 864 Ft (87 489 Ft + 5% VAT)
99 852 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 2024
- Publisher Springer
- Date of Publication 20 November 2024
- Number of Volumes 1 pieces, Book
- ISBN 9783031694905
- Binding Hardback
- No. of pages831 pages
- Size 235x155 mm
- Language English
- Illustrations 19 Illustrations, black & white; 127 Illustrations, color 664
Categories
Short description:
This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson?s disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.
MoreLong description:
This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson?s disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.
MoreTable of Contents:
Introduction to volume: Biomarkers in Psychiatry.- Part I: Government and Pharma perspectives on biomarker development.- Biomarker Methodologies: a NIMH Perspective.- Neural Circuitry-related biomarkers for drug development in psychiatry ? An industry perspective.- Public Private Partnerships for Neuropsychiatric Drug Development: A Perspective.- Part II: Biomarker methodologies and Translational Approaches.- Methods for and use of functional magnetic resonance imaging in psychiatry.- Advanced methodology for neurophysiological analysis and biomarker development: time-frequency and source-localization approaches.- Magnetoencephalography in Psychiatry: A Perspective on Translational Research and Applications.- Modern methods for unraveling cell- and circuit-level mechanisms of neurophysiological biomarkers in psychiatry.- Rodent models for ASD biomarker development.- Auditory biomarkers of neuropsychiatric disorders in nonhuman primates.- Part III: Biomarkers in schizophrenia and clinical high risk.- Functional Connectivity Biomarkers in Schizophrenia.- The use of event-related potentials in the study of schizophrenia: An overview.- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here?.- Altered sleep oscillations as neurophysiological biomarkers of schizophrenia.- Neurophysiological models in individuals at clinical high risk for psychosis: Using translational EEG paradigms to forecast psychosis risk and resilience.- Mismatch negativity (MMN) as a pharmacodynamic/response biomarker for NMDA receptor- and excitatory/inhibitory imbalance-targeted treatments in schizophrenia.- Part IV: Biomarkers in ASD.- Towards Biomarkers for Autism Spectrum Disorder: Contributions of Magnetoencephalography (MEG).- Structural Brain Imaging Biomarkers of Autism Spectrum Disorder.- Delineating a pathway for the discovery of functional connectome biomarkers of autism.- EEG Biomarkers for Autism : Rational, Support, and the Qualification Process.- Part V: Other disorders.- Translating decades of neuroscience research into diagnostic and treatment biomarkers for ADHD.- Neuroimaging Biomarkers in Parkinson?s Disease.- Biomarkers of Auditory-Verbal Hallucinations.- Part VI: Cross-diagnostic methodologies.- Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes.- Biomarkers for cognitive control, response inhibition, aggressivity, impulsivity and violence.- Visual neurophysiological biomarkers for patient stratification and treatment development across neuropsychiatric disorders.- The less things change, the more they remain the same: Impaired neural plasticity as a critical target for drug development in neuropsychiatry.
More